Adding Bortezomib to Standard Antibody-Mediated Rejection Therapy
A drug that targets antibody-producing plasma cells directly sounds like exactly what a case this advanced needs — until the randomized trial built to test that specific idea is put next to the mechanism that makes it sound appealing.
Colin B. is forty-seven, four years past a deceased-donor kidney transplant that had, until recently, let him put a rough two-year stretch mostly behind him — a job loss had briefly cost him his insurance and, with it, several months of missed clinic visits and inconsistent tacrolimus access before a new position and coverage got him back on track. He has been fully adherent and engaged with his care for the eighteen months since, which makes this month's labs land harder than they otherwise might.
His creatinine has climbed from a stable 1.4 to 2.3 over six weeks, and a for-cause biopsy shows peritubular capillaritis with diffuse C4d staining — active antibody-mediated rejection, not a recurrence of the earlier adherence gap showing up as simple underdosing. A donor-specific antibody previously undetectable on his surveillance panels is now present at a meaningful titer. This is a more established, later-presenting rejection than the kind caught within weeks of onset, and the team's disagreement isn't about whether to treat it — that part is settled — but about whether an agent that reaches further upstream, targeting the antibody-producing plasma cells directly rather than removing circulating antibody or depleting B cells, belongs in his regimen given how advanced this presentation already is.
He is candid, almost apologetic, about the gap two years ago — he knows exactly which months he missed and can name the specific refill he let lapse when the new insurance card still hadn't arrived. That candor matters to how the team reads today's labs: this isn't a rejection quietly accumulating during a period of unrecognized underdosing, since his tacrolimus levels have been consistently in range for the entire eighteen months his adherence has been solid. Whatever triggered this new antibody, it triggered on a foundation of a regimen that was, by every available measure, actually being taken.
Transplant clinic, treating active AMR
Standard therapy — plasma exchange, IVIG, and rituximab — is the most guideline-referenced, most widely tested combination for active AMR, and despite imperfect evidence across the field, it's what I'd start today. It's not a fallback we reach for absent something better; it's the appropriate first-line regimen on its own terms.
I'd add bortezomib to that regimen, specifically because of how established this rejection already is. Rituximab depletes B cells, but by the time antibody-producing plasma cells have fully differentiated — which four years post-transplant, presenting with a meaningful new DSA titer, strongly suggests has already happened — B-cell depletion alone may not reach the actual source of the antibody. A proteasome inhibitor targets those plasma cells directly, mechanistically closer to the real driver of his rejection than anything in the standard combination touches.
You're right that the mechanism is genuinely appealing, and I don't think that argument is wrong on its face — plasma cells are a real gap in what rituximab reaches. But the specific question of whether adding bortezomib actually helps in exactly this kind of late, established AMR has already been tested directly: the BORTEJECT trial randomized bortezomib add-on against standard therapy in this setting and found no benefit on the outcomes that matter, despite the same mechanistic logic driving the hypothesis going in.
Bortezomib isn't free to add on spec — real peripheral neuropathy and cytopenia risk come with it. Without a demonstrated benefit in the population that trial actually studied, and his presentation matching that population closely, I don't think the mechanism alone justifies adding it here. I'd start standard therapy and track his DSA titer and creatinine closely instead.
Agreed: standard therapy — plasma exchange, IVIG, and rituximab — started without bortezomib. The pharmacist's citation of the BORTEJECT trial's negative result was accepted by the immunologist as decisive against adding an agent whose real toxicity wasn't justified by that trial's own findings, despite the mechanism remaining genuinely appealing in the abstract.
Not agreed: how quickly to consider a repeat biopsy if his DSA titer and creatinine haven't meaningfully improved after standard therapy completes. The immunologist wants a two-week follow-up biopsy regardless of trend, arguing his more established rejection may need earlier reassessment than a typical case; the physician would rather follow serial labs first and reserve a repeat biopsy for a case where the trend itself, not a fixed calendar date, suggests standard therapy isn't working.